Allergoscope new program
Milton Essex is developing a new project called Allergoscope.
miltonessex.euCrawled Nov 20, 2026
Milton Essex is developing a new project called Allergoscope.
The company’s project under the Smart Growth Operational Program 2014–2020 aims to create a solution for infrared imaging of skin allergy responses. The innovation involves adding instrumental reading to existing skin tests.
The FOTONICA FACE COV FIRIMAS project under the Smart Growth Operational Program 2014–2020 focuses on using artificial intelligence to advance photonic solutions in automated medical diagnostic systems.
The World Allergy Organization ranks allergies as the third most common chronic disease and a global health priority.
The 2019 market analysis summarizes allergy specialty and care statistics for Europe, based on a study by Fyhrquist et al.
Allergy tests detect allergies by exposing patients to allergens and observing their reactions.
Milton Essex S.A. and DM Navigator S.A. completed an investment subscription for 2.75 million Series L shares in July 2020.
Milton Essex received 6.9 million zł in funding from Narodowe Centrum Badań i Rozwoju for the FACE-COV project with Wojskowa Akademia Techniczna.
Milton Essex S.A., leading the R&D consortium with Instytut Optoelektroniki WAT, secured funding for the FACE-COV project to develop a thermal imaging system for detecting infection symptoms, including SARS-CoV-2.
Milton Essex showcased the SkinSENS and FaceCOV systems at MEDICA in Düsseldorf, November 15–18, 2021.
Polish researchers are developing a system for rapid identification of SARS-CoV-2 infection markers using thermal imaging.
Milton Essex displayed SkinSENSE and FaceCOV systems at the International Defense Industry Fair, partnering with Wojskowa Akademia Techniczna.
Milton Essex issued a request for proposals for a chief medical researcher under contract, with submissions due September 15, 2023.
Milton Essex issued a request for proposals for a medical doctor or nurse under contract, with submissions due September 15, 2023.
The company’s project team combines R&D, strategy, and development expertise, including industry 4.0, marketing, EU funds, and knowledge management.
Milton Essex S.A. received ethical approval for a clinical trial of a medical device on December 12, 2022.
The management team combines legal, scientific, and managerial expertise, including Dr. Jacek Stępień, leader of the FOTONICA consortium.
Milton Essex S.A. develops new diagnostic methods using medical systems, imaging technologies, and digital solutions.
The company conducted electromagnetic compatibility (EMC) testing on the SkinSENSE device in February 2021 as part of the FOTONICA project (Fully-automated Optoelectronic System for Noninvasive Imaging in Clinical Applications).
The company issued a request for proposals on March 3, 2021, for a mechanical engineer under contract to work on the FOTONICA project (Fully-automated Optoelectronic System for Noninvasive Imaging in Clinical Applications). Bids were due by March 31, 2021.
Milton Essex sought an engineer-designer for the FOTONICA project, focusing on AI-supported photonic solutions for medical diagnostics.
Milton Essex offers SkinSENS for skin allergy diagnostics and the Allergoscope program.
Milton Essex SA provides a privacy policy for personal data protection.